Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Targeting tyrosine kinase receptors that share the feedback inhibitor PTPN12 leads to broad spectrum therapeutic suppression of triple-negative breast cancer.
Genomic and drug screens identify SHP2 blockade as a therapeutic approach for ALK-rearranged non-small cell lung cancers developing resistance through ALK-mutant-independent mechanisms.
The small molecule H3B-8800 selectively modulates RNA splicing to preferentially kill tumor cells bearing mutations in genes encoding spliceosome components.
Optimal T cell activation requires signaling through the T cell receptor (signal 1), a co-stimulatory receptor (signal 2) and a cytokine receptor (signal 3), yet most chimeric antigen receptors (CARs) lack a domain to transduce signal 3. Kagoya et al. now report their development of a new CAR that incorporates a JAK–STAT cytokine signaling domain and mediates potent antitumor effects.
A small-molecule antagonist of PPAR-γ expands human cord blood HSPCs via downregulation of fructose 1,6-bisphosphatase expression, thereby enhancing glycolysis.
Myeloid-derived suppressor cells are induced in newborn mice by breast-milk-derived lactoferrin and confer protection in a model of necrotizing enterocolitis. Their frequency and suppressive activity is decreased in very low-weight infants.
A luteinizing hormone–releasing hormone antagonist, used clinically for sex-steroid inhibition, promotes quiescence of hematopoietic stem cells and thereby promotes hematopoietic recovery and survival of lethally irradiated mice.